Antipsychotic drugs may have to carry warnings about weight gain and diabetes, says the U.S. Food and Drug Administration. The drugs' labels currently include information about weight gain and associated problems, but the FDA is considering requiring that information be included in the warnings section.
The agency has asked manufacturers of antipsychotic drugs for all the information they have about metabolic side effects, such as increases in blood glucose and blood cholesterol levels, Dow Jones Newswires reported.
The drugs that may be affected by the label change include Seroquel, Abilify, Zyprexa, Risperdal and Geodon. These drugs are used to treat conditions such as depression, schizophrenia and bipolar disorder.
Studies have suggested that the weight gain impact of antipsychotic drugs is stronger in children than in adults, Dow Jones reported.